Deciphering VEXAS Syndrome: From UBA1 Somatic Mutations to Precision Management and Allo-HSCT

Deciphering VEXAS Syndrome: From UBA1 Somatic Mutations to Precision Management and Allo-HSCT

During the recent workshop "Focus on Allogeneic HSCT in Myelodysplastic Syndromes," Professor Fabio Ciceri (IRCCS San Raffaele Scientific Institute / Vita-Salute San Raffaele University), Chair of the EBMT Scientific Council and the Acute Leukemia Working Party (ALWP), provided a comprehensive overview of "Contemporary Approaches to VEXAS." He systematically detailed the genetic foundations, clinical progression, and multidimensional therapeutic landscape of this complex disease.
Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia

Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.
EAU26 Afternoon Dialogue | Xuesong Li: ADC Plus Radiotherapy in the Perioperative Setting Breaks Therapeutic Barriers and Opens a New Era of Precision Treatment for UTUC

EAU26 Afternoon Dialogue | Xuesong Li: ADC Plus Radiotherapy in the Perioperative Setting Breaks Therapeutic Barriers and Opens a New Era of Precision Treatment for UTUC

At the 2026 European Association of Urology Congress (EAU26), held in London, major advances in urologic oncology were presented. Among them, the work of Professor Xuesong Li’s team from Peking University First Hospital attracted considerable attention. The team not only contributed important achievements in upper urinary tract reconstruction but also presented a phase II clinical study of disitamab vedotin combined with radiotherapy for upper tract urothelial carcinoma (UTUC), offering a promising new treatment option.
EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL

EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL

Patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have an extremely poor prognosis. Historically, treatment options have been limited, and even with a second transplant, long-term survival has remained below 30%. There is therefore an urgent need for more effective therapeutic strategies.
EAU26 | Professor Yi-Jun Shen on the HERO Study: Disitamab Vedotin Plus BCG Shows Promise in HR-NMIBC 

EAU26 | Professor Yi-Jun Shen on the HERO Study: Disitamab Vedotin Plus BCG Shows Promise in HR-NMIBC 

Non–muscle-invasive bladder cancer (NMIBC) carries a substantial risk of postoperative recurrence, particularly in high-risk and very high-risk patients, where the 5-year recurrence rate can exceed 50%. In recent years, beyond traditional Bacillus Calmette–Guérin (BCG) intravesical therapy, the emergence of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) has provided new therapeutic options to reduce recurrence risk in high-risk NMIBC.
Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL

Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL

Although CD19 CAR-T therapy achieves high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), relapse driven by CD19 antigen loss poses a major challenge for MRD monitoring and long-term disease management. Identifying more stable biomarkers has therefore become essential for improving response assessment and prognostic evaluation.
EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

The 2026 European Association of Urology Annual Congress (EAU26), held in London, once again served as a premier platform showcasing cutting-edge advances in urologic oncology. At this year’s meeting, Prof. Kan Gong and his team from Peking University First Hospital presented a series of impactful studies focusing on von Hippel–Lindau (VHL) syndrome–associated renal cell carcinoma in the Chinese population.
Prof. Enrique Gallardo: Final OS Results from PEACE-3 Trial — Enzalutamide Plus Radium-223 Reshapes the mCRPC Treatment Landscape

Prof. Enrique Gallardo: Final OS Results from PEACE-3 Trial — Enzalutamide Plus Radium-223 Reshapes the mCRPC Treatment Landscape

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, bringing forward several landmark advances in prostate cancer. Among them, the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial represent a major milestone in the management of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
Shifting Paradigms in MIBC Diagnosis: How Multimodal Imaging Staging Optimizes Clinical Decision-Making 

Shifting Paradigms in MIBC Diagnosis: How Multimodal Imaging Staging Optimizes Clinical Decision-Making 

During the recent academic session, Professor Antoine Van Der Heijden from Radboud University Medical Center (Nijmegen, NL) shared comprehensive insights into the management of Muscle-Invasive Bladder Cancer (MIBC). The presentation focused on the clinical significance of histological subtypes, the inherent limitations of traditional Transurethral Resection of Bladder Tumor (TURBT), and the emerging value of MRI and Vi-RADS scoring in precision staging.